Physicians' interpretation of "class effects": A need for thoughtful re-evaluation

Journal of the American College of Cardiology

Volumn 40, Issue 1, 2002, Pages 19-26

  Kennedy, Harold L ^a,c   Rosenson, Robert S ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Bay Pines VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; METOPROLOL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CLINICAL PRACTICE; CLINICAL TRIAL; CONCEPT FORMATION; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MEDICAL PRACTICE; OUTCOMES RESEARCH; PERCEPTION; PHYSICIAN; POLICY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ATTITUDE OF HEALTH PERSONNEL; CARDIOVASCULAR AGENTS; DRUG INDUSTRY; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037014636     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01913-7     Document Type: Review

References (95)

1. Electrophysiological effects of labetolol on rabbit atrial, ventricular and Purkinje cells, in normoxia and hypoxia
2. Antifibrillatory versus antiectopic therapy
3. The search for novel antiarrhythmlc strategies: Sicilian gambit
4. Effects of enalapril on mortality in severe congestive heart failure
5. Guidelines for the evaluation and management of heart failure
6. Heart failure: Evaluation and care of patients with left-ventricular systolic dysfunction
7. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?
8. Use of "Xapril" in patients with chronic heart failure: A paradigm or epitah for our times
9. Are all angiotensin-converting enzyme inhibitors interchangeable?
10. Are drugs within a class interchangeable?
11. Pharmacogenetics and future drug development and delivery
12. Knowledge and practice of generalist and specialist physicians regarding drug therapy for acute myocardial infarction
13. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
14. Potential proischemic effect of early enalapril in hypotension- prone patients with acute myocardial infarction: The CONSENSUS II Holter substudy group
15. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on-6-week mortality and ventricular function after acute myocardial infarction
16. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
17. Therapeutic class wars - Drug promotion in a competitive marketplace
18. The importance of randomized clinical trials and evidence-based medicine: A clinician's perspective
19. Prostacyclin: Its pathogenic role in essential hypertension and the class effects of ACE inhibitors on prostaglandin metabolism
20. Publication bias: The problem that won't go away
21. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials
22. Uneasy alliance: Clinical investigators and the pharmaceutical industry
23. Company sought to block paper's publication
24. HMOs: Origins and development
25. A national bill of patients' rights
26. Physician use of beta-adrenergic blocking therapy: A changing perspective
27. Beta-blocker Heart Attack Research Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results
28. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction
29. Xamoterol in severe heart failure
30. The xamoterol experience in the treatment of heart failure
31. Effects of beta receptor antagonists on left ventricular function patients with clinical evidence of heart failure after myocardial infarction. A double-blind comparison of metoprolol and xamoterol. Echocardiographic results from the Metoprolol and Xamoterol Infarction Study (MEXIS)
32. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: Metoprolol in Dilated Cardiomyopathy (MDC) trial
33. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol
34. Persistent reduction of mortality for five years after one year of acebutolol treatment initiated during acute myocardial infarction
35. A randomized trail of beta-blockade in heart failure: The cardiac insufficiency bisoprolol study (CIBIS)
36. Reliable assessment of the effects of treatment on mortality and major morbidity: I. Clinical trials
37. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
38. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
39. Second- and third-generation beta- blocking drugs in chronic heart failure
40. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
41. Beta-adrenergic receptor blockade in chronic heart failure
42. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure
43. Effect of Beta-blockade on mortality in African-Americans: The Beta-blocker Evaluation of Survival Trial
44. Failure of benefit and early hazard of bucindolol in class IV heart failure
45. Implications of discontinuation of doxazosin arm of ALLHAT
46. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone: The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
47. Effect of carvedilol on survival in severe chronic heart failure
48. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure
49. Responsiveness to alpha-and beta-adrenergic receptor agonists: Effect of race in borderline hypertensive compared to normotensive men
50. Racial differences in epinephrine and beta 2-adrenergic receptors
51. Racial differences in the response to drugs - Pointers to genetic differences
52. Adrenergic receptor polymorphisms and cardiac function (and dysfunction)
53. 2-adrenergic receptor on agonist-mediated vascular desensitization
54. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction
55. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure
56. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival And Ventricular Enlargement trial
57. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Systematic overview of individual data from 100,000 patients in randomized trials
58. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients
59. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure
60. Quinaprilat induces arterial vasodilation mediated by nitric oxide in humans
61. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction
62. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction
63. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
64. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure
65. Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction
66. Non-lipid lowering effects of statins on atherosclerosis
67. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
68. Inhibition of proliferation of human smooth muscle ceils by various HMG-CoA reductase inhib; comparison with other human cell types
69. Activation of human aortic smooth-muscle cells is inhibited by PRARα but not by PPARγ activators
70. Lipophilic statins sensitize human smooth muscle cells to Fas-mediated cell death
71. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits
72. Inhibition of proinflammatory cytokine production by pravastatin
73. Vastatins inhibit tissue factor in cultured human macrophages
74. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
75. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemlc rabbits
76. Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins
77. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin
78. Statins as a newly recognized type of immunomodulator
79. "Slim" chance Baycol will return
80. Cerivastatin and reports of fatal rhabdomyolysis
81. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
82. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian Simvastatin Survival Study
83. The Asp9Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis
84. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
85. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
86. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
87. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
88. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study
89. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
90. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
91. Lipid-lowering therapy in acute coronary syndromes
92. Overcoming the limitations of current meta-analysis of randomised controlled trials
93. Is academic medicine for sale?